2019年血液与骨髓移植临床试验网络骨髓瘤协作组微小残留病与免疫分析研讨会总结
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
作者信息
Holstein Sarah A, Howard Alan, Avigan David, Bhutani Manisha, Cohen Adam D, Costa Luciano J, Dhodapkar Madhav V, Gay Francesca, Gormley Nicole, Green Damian J, Hillengass Jens, Korde Neha, Li Zihai, Mailankody Sham, Neri Paola, Parekh Samir, Pasquini Marcelo C, Puig Noemi, Roodman G David, Samur Mehmet Kemal, Shah Nina, Shah Urvi A, Shi Qian, Spencer Andrew, Suman Vera J, Usmani Saad Z, McCarthy Philip L
机构信息
University of Nebraska Medical Center, Omaha, Nebraska.
Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota.
出版信息
Biol Blood Marrow Transplant. 2020 Oct;26(10):e247-e255. doi: 10.1016/j.bbmt.2020.06.011. Epub 2020 Jun 24.
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup has organized an annual workshop focused on minimal residual disease (MRD) testing and immune profiling (IP) in multiple myeloma since 2016. In 2019, the workshop took place as an American Society of Hematology (ASH) Friday Scientific Workshop titled "Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma." This workshop focused on 4 main topics: the molecular and immunologic evolution of plasma cell disorders, development of new laboratory- and imaging-based MRD assessment approaches, chimeric antigen receptor T cell therapy research, and statistical and regulatory issues associated with novel clinical endpoints. In this report, we provide a summary of the workshop and discuss future directions.
自2016年以来，血液与骨髓移植临床试验网络（BMT CTN）骨髓瘤协作组每年都会组织一次研讨会，重点关注多发性骨髓瘤的微小残留病（MRD）检测和免疫谱分析（IP）。2019年，该研讨会作为美国血液学会（ASH）周五科学研讨会举行，主题为“多发性骨髓瘤的免疫谱分析和微小残留病检测”。本次研讨会聚焦4个主要主题：浆细胞疾病的分子和免疫进化、基于实验室和影像学的新MRD评估方法的开发、嵌合抗原受体T细胞疗法研究，以及与新型临床终点相关的统计和监管问题。在本报告中，我们对研讨会进行了总结并探讨了未来方向。
Zotero 插件